Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme

• Published in: Metabolites 2020-06, Vol.10 (6), p.258
• Main Authors: Singh, Rajbir, Chandrashekharappa, Sandeep, Vemula, Praveen Kumar, Haribabu, Bodduluri, Jala, Venkatakrishna Rao
• Format: Article
• Language: English
• Subjects: Amine oxidase (flavin-containing); Binding sites; Bioavailability; Brain; Communication; Dopamine; Ellagic acid; Enzyme kinetics; Inflammation; Intestinal microflora; Mental depression; Metabolites; microbial metabolites; Microbiota; monoamine oxidase; Monoamines; Movement disorders; Neurodegenerative diseases; Neurological diseases; Neuroprotection; Neurotransmitters; Oxidants; Parkinson's disease; urolithins
• ISSN: 2218-1989; 2218-1989
• DOI: 10.3390/metabo10060258

Urolithins are gut microbial metabolites derived from ellagitannins (ET) and ellagic acid (EA), and shown to exhibit anticancer, anti-inflammatory, anti-microbial, anti-glycative and anti-oxidant activities. Similarly, the parent molecules, ET and EA are reported for their neuroprotection and antidepressant activities. Due to the poor bioavailability of ET and EA, the in vivo functional activities cannot be attributed exclusively to these compounds. Elevated monoamine oxidase (MAO) activities are responsible for the inactivation of monoamine neurotransmitters in neurological disorders, such as depression and Parkinson’s disease. In this study, we examined the inhibitory effects of urolithins (A, B and C) and EA on MAO activity using recombinant human MAO-A and MAO-B enzymes. Urolithin B was found to be a better MAO-A enzyme inhibitor among the tested urolithins and EA with an IC50 value of 0.88 µM, and displaying a mixed mode of inhibition. However, all tested compounds exhibited higher IC50 (>100 µM) for MAO-B enzyme.